Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism
- PMID: 6420216
- DOI: 10.2337/diab.33.2.130
Glucosylation of low-density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism
Abstract
In previous studies we have shown that extensive glucosylation of low-density lipoproteins (LDL) (40% of lysines modified) completely blocks receptor-mediated degradation in animals and in man. Other studies indicated that in some diabetics up to 5% of lysine residues of LDL were glucosylated. The present study was done to determine if the extent of glucosylation of LDL which can occur in diabetics could alter LDL catabolism. We measured degradation by cultured normal human fibroblasts and turnover in guinea pigs of various LDLs with 2-17% of lysine residues glucosylated. Modification of as few as 2-5% of lysines decreased LDL catabolism by 5-25%, and the degree of inhibition of catabolism was linearly related to the extent of LDL glucosylation. These results indicate that the extent of LDL glucosylation that can occur in diabetes may slow LDL catabolism and hence increase plasma LDL levels.
Similar articles
-
Limited nonenzymatic glucosylation of low-density lipoprotein does not alter its catabolism in tissue culture.Biochim Biophys Acta. 1985 Aug 30;846(2):226-33. doi: 10.1016/0167-4889(85)90069-2. Biochim Biophys Acta. 1985. PMID: 3927987
-
Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity.Diabetes. 1982 Apr;31(4 Pt 1):283-91. doi: 10.2337/diab.31.4.283. Diabetes. 1982. PMID: 6818075
-
Comparison of glucosylated low density lipoprotein with methylated or cyclohexanedione-treated low density lipoprotein in the measurement of receptor-independent low density lipoprotein catabolism.J Clin Invest. 1983 Apr;71(4):960-4. doi: 10.1172/jci110850. J Clin Invest. 1983. PMID: 6300195 Free PMC article.
-
[Metabolic consequences of the nonenzymatic glucosylation of apolipoproteins].Diabete Metab. 1991 Nov-Dec;17(6):497-502. Diabete Metab. 1991. PMID: 1809594 Review. French.
-
Pathophysiology of low density lipoprotein and high density lipoprotein glucosylation.Monogr Atheroscler. 1985;13:63-73. Monogr Atheroscler. 1985. PMID: 3911060 Review. No abstract available.
Cited by
-
Pathophysiology of diabetic dyslipidaemia: where are we?Diabetologia. 2015 May;58(5):886-99. doi: 10.1007/s00125-015-3525-8. Epub 2015 Mar 1. Diabetologia. 2015. PMID: 25725623 Free PMC article. Review.
-
The effects of antihypertensive drugs on serum lipids and lipoproteins, I. Diuretics.Drugs. 1986 Sep;32(3):260-78. doi: 10.2165/00003495-198632030-00003. Drugs. 1986. PMID: 3530704 Review.
-
Circulating lipids and glycaemic control in insulin dependent diabetic children.Arch Dis Child. 1994 Aug;71(2):108-13. doi: 10.1136/adc.71.2.108. Arch Dis Child. 1994. PMID: 7944528 Free PMC article.
-
Glucose oxidation and low-density lipoprotein-induced macrophage ceroid accumulation: possible implications for diabetic atherosclerosis.Biochem J. 1994 May 15;300 ( Pt 1)(Pt 1):243-9. doi: 10.1042/bj3000243. Biochem J. 1994. PMID: 8198540 Free PMC article.
-
Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine.J Lipid Res. 2014 Oct;55(10):2137-55. doi: 10.1194/jlr.M053256. Epub 2014 Aug 20. J Lipid Res. 2014. PMID: 25143462 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical